**Solid improvement in rigor, but the clinical utility claim is still limited by interval width and decision ambiguity.**

### What is now scientifically stronger

- **Strict unexposed set (22 variants)** with clear partition labels (9 pure TEST + 13 CALIB) is the right design. Zero training mutations is correctly enforced.
- **100 % containment on all 9 pure TEST variants** across all three antibiotics is the strongest generalization result in the report.
- Inclusion of both BLDB hospital strains and Chen et al. wet-lab EC₅₀ mutants (Set B) gives better label provenance.
- Zero false-safety errors remains the most important safety property.
- Binary classification metrics on the 612 held-out test positions are reasonable (≈77–81 % accuracy, high NPV).

### Persistent and new issues

**1. Almost every clinical call is “Ambiguous (Triage for Lab)”**  
This is the dominant practical limitation.  
Even though containment is high, the two-sided intervals are still so wide that the model almost never issues a decisive **Certified Resistant** or **Certified Susceptible** call on these 22 variants. In a real clinical workflow this means nearly everything is still sent to the wet lab — defeating much of the point of certified decision support.

**2. Interval widths remain large**  
- AMP mean width ≈ 14.7 log₂ units  
- CTX ≈ 8.3, MEM ≈ 8.8  

These are still a substantial fraction of the assay dynamic range. High containment under such widths is expected and does not demonstrate high precision.

**3. M154L point-estimate bias is unchanged and large**  
$\hat{\mu}$ is still strongly negative while true fitness is positive. Containment occurs only because of the wide interval. The DCI_asym table has also flipped sign convention compared with earlier reports (now showing positive “Driver” values); this needs consistency checks.

**4. One failure on Meropenem**  
M248L is not contained on MEM (true $y = +1.22$, upper bound $+1.14$). This is the single miss in the 22-variant set and should be discussed.

**5. Missing certified decision breakdown**  
You still need the counts of:
- Certified Resistant  
- Certified Susceptible  
- Ambiguous  

on both the 22 clinical variants and the full 612 test set. Without those numbers the “decision utility” claim remains incomplete.

### Recommended next actions (in priority order)

1. **Switch the primary clinical guarantee to the one-sided upper conformal bound** you already designed.  
   This will shrink the relevant margin to ~3.3–4.7 units and should convert many currently Ambiguous cases into decisive upper-bound calls.

2. Report the full Certified Resistant / Susceptible / Ambiguous counts under both two-sided and one-sided rules.

3. Explicitly acknowledge the M154L point-estimate failure and the remaining width limitation.

4. Keep the current 22-variant table (it is clean). Optionally add a short sensitivity note on the single Meropenem miss (M248L).

**Bottom line**  
The validation set construction is now rigorous and the pure held-out containment result is good. However, because virtually every clinical variant is still labelled “Ambiguous” under two-sided intervals, the report does not yet demonstrate strong *actionable* clinical decision utility. Implementing the one-sided upper bound and adding the decisive-call statistics would address the main remaining weakness.